

# Rafael LeÃ³n

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9104524/publications.pdf>

Version: 2024-02-01

68  
papers

3,579  
citations

196777

29  
h-index

175968

55  
g-index

74  
all docs

74  
docs citations

74  
times ranked

6025  
citing authors

#	ARTICLE	IF	CITATIONS
1	Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157â€‘Lipoic Acid Hybrids for the Treatment of Alzheimerâ€™s Disease. <i>Antioxidants</i> , 2022, 11, 112.	2.2	1
2	Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinsonâ€™s Disease. <i>Antioxidants</i> , 2022, 11, 247.	2.2	4
3	Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 4727-4751.	2.9	10
4	Curcumin-Piperlongumine Hybrids with a Multitarget Profile Elicit Neuroprotection in In Vitro Models of Oxidative Stress and Hyperphosphorylation. <i>Antioxidants</i> , 2022, 11, 28.	2.2	4
5	Bisavenathramide Analogues as Nrf2 Inducers and Neuroprotectors in In Vitro Models of Oxidative Stress and Hyperphosphorylation. <i>Antioxidants</i> , 2021, 10, 941.	2.2	13
6	Enhanced Stability and Bioactivity of Natural Anticancer Topoisomerase I Inhibitors through Cyclodextrin Complexation. <i>Pharmaceutics</i> , 2021, 13, 1609.	2.0	15
7	Azaâ€‘CGP37157â€‘lipoic hybrids designed as novel Nrf2â€‘inducers and antioxidants exert neuroprotection against oxidative stress and show neuroinflammation inhibitory properties. <i>Drug Development Research</i> , 2020, 81, 283-294.	1.4	4
8	Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization. <i>Pharmacological Research</i> , 2020, 152, 104597.	3.1	13
9	Antioxidant, Anti-inflammatory and Neuroprotective Profiles of Novel 1,4-Dihydropyridine Derivatives for the Treatment of Alzheimerâ€™s Disease. <i>Antioxidants</i> , 2020, 9, 650.	2.2	18
10	Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches. <i>Handbook of Experimental Pharmacology</i> , 2020, 264, 229-259.	0.9	20
11	When It Comes to an End: Oxidative Stress Crosstalk with Protein Aggregation and Neuroinflammation Induce Neurodegeneration. <i>Antioxidants</i> , 2020, 9, 740.	2.2	52
12	NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases. <i>Biomolecules</i> , 2020, 10, 904.	1.8	50
13	Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties. <i>European Journal of Medicinal Chemistry</i> , 2020, 190, 112090.	2.6	15
14	Nrf2 Plays a Protective Role Against Intravascular Hemolysis-Mediated Acute Kidney Injury. <i>Frontiers in Pharmacology</i> , 2019, 10, 740.	1.6	36
15	Pharmacological doses of melatonin impede cognitive decline in tauâ€‘related Alzheimer models, once tauopathy is initiated, by restoring the autophagic flux. <i>Journal of Pineal Research</i> , 2019, 67, e12578.	3.4	53
16	Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. <i>Pharmacological Reviews</i> , 2018, 70, 348-383.	7.1	441
17	The <sc>APP</sc>/<sc>PS</sc>1A246E mutations in an astrocytic cell line leads to increased vulnerability to oxygen and glucose deprivation, Ca<sup>2+</sup> dysregulation, and mitochondrial abnormalities. <i>Journal of Neurochemistry</i> , 2018, 145, 170-182.	2.1	4
18	MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species. <i>Translational Research</i> , 2018, 200, 1-17.	2.2	28

#	ARTICLE	IF	CITATIONS
19	Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia. <i>European Journal of Medicinal Chemistry</i> , 2017, 130, 60-72.	2.6	21
20	Addition to $\alpha$ -ITH14001, a CGP37157-Nimodipine Hybrid Designed to Regulate Calcium Homeostasis and Oxidative Stress, Exerts Neuroprotection in Cerebral Ischemia. <i>ACS Chemical Neuroscience</i> , 2017, 8, 210-210.	1.7	2
21	Discovery of the first dual GSK3 $\beta$ inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 45701.	1.6	59
22	Novel sulfoglycolipid IG20 causes neuroprotection by activating the phase II antioxidant response in rat hippocampal slices. <i>Neuropharmacology</i> , 2017, 116, 110-121.	2.0	1
23	Saffron ( <i>Crocus sativus</i> ) intake provides nutritional preconditioning against myocardial ischemia-reperfusion injury in Wild Type and ApoE ( $\Delta$ ) mice: Involvement of Nrf2 activation. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 919-929.	1.1	29
24	Inclusion complex of ITH12674 with 2-hydroxypropyl- $\beta$ -cyclodextrin: Preparation, physical characterization and pharmacological effect. <i>Carbohydrate Polymers</i> , 2017, 157, 94-104.	5.1	49
25	ITH14001, a CGP37157-Nimodipine Hybrid Designed to Regulate Calcium Homeostasis and Oxidative Stress, Exerts Neuroprotection in Cerebral Ischemia. <i>ACS Chemical Neuroscience</i> , 2017, 8, 67-81.	1.7	20
26	Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer's Disease. <i>Current Topics in Medicinal Chemistry</i> , 2017, 17, 1027-1043.	1.0	18
27	The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9967-9973.	2.9	83
28	Serine/threonine protein phosphatase PP2A as a relevant target of disulphide stress in acute pancreatitis. <i>Free Radical Biology and Medicine</i> , 2016, 96, S62-S63.	1.3	0
29	Nrf2-ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases. , 2016, 157, 84-104.		463
30	Subthreshold Concentrations of Melatonin and Galantamine Improves Pathological AD-Hallmarks in Hippocampal Organotypic Cultures. <i>Molecular Neurobiology</i> , 2016, 53, 3338-3348.	1.9	23
31	Alpha7 nicotinic receptor activation protects against oxidative stress via heme-oxygenase I induction. <i>Biochemical Pharmacology</i> , 2015, 97, 473-481.	2.0	34
32	Neuroprotective mechanism of the novel melatonin derivative Neu-P11 in brain ischemia related models. <i>Neuropharmacology</i> , 2015, 99, 187-195.	2.0	34
33	New melatonin-cinnamate hybrids as multi-target drugs for neurodegenerative diseases: Nrf2-induction, antioxidant effect and neuroprotection. <i>Future Medicinal Chemistry</i> , 2015, 7, 1961-1969.	1.1	28
34	Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection. <i>Biochemical Pharmacology</i> , 2015, 97, 463-472.	2.0	228
35	Melatonin-sulforaphane hybrid ITH12674 induces neuroprotection in oxidative stress conditions by a drug-prodrug mechanism of action. <i>British Journal of Pharmacology</i> , 2015, 172, 1807-1821.	2.7	36
36	The Melatonin-N-Dibenzyl-N-methylamine Hybrid ITH91/IQM157 Affords Neuroprotection in an in Vitro Alzheimer's Model via Hemo-oxygenase-1 Induction. <i>ACS Chemical Neuroscience</i> , 2015, 6, 288-296.	1.7	27

#	ARTICLE	IF	CITATIONS
37	Neuroprotective effect of dimebon against ischemic neuronal damage. <i>Neuroscience</i> , 2014, 267, 11-21.	1.1	10
38	New 5-Unsubstituted Dihydropyridines with Improved Ca <sup>v</sup> 1.3 Selectivity as Potential Neuroprotective Agents against Ischemic Injury. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4313-4323.	2.9	43
39	Gram-scale Enantioselective Formal Synthesis of Morphine through an ortho-para Oxidative Phenolic Coupling Strategy. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 13498-13501.	7.2	46
40	Neuroprotective effect of melatonin against ischemia is partially mediated by alpha7 nicotinic receptor modulation and HO-1 overexpression. <i>Journal of Pineal Research</i> , 2014, 56, 204-212.	3.4	93
41	Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. <i>Medicinal Research Reviews</i> , 2013, 33, 139-189.	5.0	394
42	Novel multitarget ligand ITH33/IQM9.21 provides neuroprotection in in vitro and in vivo models related to brain ischemia. <i>Neuropharmacology</i> , 2013, 67, 403-411.	2.0	25
43	Identification of 4,6-diaryl-1,4-dihydropyridines as a new class of neuroprotective agents. <i>MedChemComm</i> , 2013, 4, 590.	3.5	22
44	Benzothiazepine CGP37157 and Its Isosteric 2-Methyl Analogue Provide Neuroprotection and Block Cell Calcium Entry. <i>ACS Chemical Neuroscience</i> , 2012, 3, 519-529.	1.7	26
45	Catalytic enantioselective assembly of complex molecules containing embedded quaternary stereogenic centres from simple anisidine derivatives. <i>Chemical Science</i> , 2011, 2, 1487.	3.7	120
46	A Step Further Towards Multitarget Drugs for Alzheimer and Neuronal Vascular Diseases: Targeting the Cholinergic System, Amyloid- $\beta$ Aggregation and Ca <sup>2+</sup> Dyshomeostasis. <i>Current Medicinal Chemistry</i> , 2011, 18, 552-576.	1.2	50
47	Calcium signalling mediated through $\alpha 7$ and non- $\alpha 7$ nAChR stimulation is differentially regulated in bovine chromaffin cells to induce catecholamine release. <i>British Journal of Pharmacology</i> , 2011, 162, 94-110.	2.7	27
48	Synthesis and biological assessment of diversely substituted furo[2,3-b]quinolin-4-amine and pyrrolo[2,3-b]quinolin-4-amine derivatives, as novel tacrine analogues. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 6119-6130.	2.6	46
49	Effects of novel tacripyrines ITH12117 and ITH12118 on rat vas deferens contractions, calcium transients and cholinesterase activity. <i>European Journal of Pharmacology</i> , 2011, 660, 411-419.	1.7	5
50	N-Acylaminophenothiazines: Neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 2224-2235.	2.6	46
51	Elucidating the reaction mechanism of the benzoate oxidation pathway encoded aldehyde dehydrogenase from <i>Burkholderia xenovorans</i> LB400. <i>Protein Science</i> , 2011, 20, 1048-1059.	3.1	3
52	Synthesis, Inhibitory Activity of Cholinesterases, and Neuroprotective Profile of Novel 1,8-Naphthyridine Derivatives. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 5129-5143.	2.9	69
53	Structural and Biophysical Characterization of BoxC from <i>Burkholderia xenovorans</i> LB400. <i>Journal of Biological Chemistry</i> , 2009, 284, 16377-16385.	1.6	12
54	A reinvestigation of the acid-promoted heterocyclization of 2-(2-oxo-2-arylethyl)malonitriles in the presence of amines. <i>Molecular Diversity</i> , 2009, 13, 459-468.	2.1	6

#	ARTICLE	IF	CITATIONS
55	The N-terminal tripeptide of insulin-like growth factor protects against $\beta$ -amyloid-induced somatostatin depletion by calcium and glycogen synthase kinase 3 $\beta$ modulation. <i>Journal of Neurochemistry</i> , 2009, 109, 360-370.	2.1	33
56	Tacripyrines, the First Tacrine-Dihydropyridine Hybrids, as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2724-2732.	2.9	134
57	Identification and Characterization of Binding Sites on S100A7, a Participant in Cancer and Inflammation Pathways. <i>Biochemistry</i> , 2009, 48, 10591-10600.	1.2	20
58	Synthesis of 6-amino-1,4-dihydropyridines that prevent calcium overload and neuronal death. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 668-674.	2.6	33
59	New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 7759-7769.	1.4	75
60	Novel Multipotent Tacrine-Dihydropyridine Hybrids with Improved Acetylcholinesterase Inhibitory and Neuroprotective Activities as Potential Drugs for the Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7607-7610.	2.9	107
61	Synthesis and biological evaluation of new 4H-pyrano[2,3-b]quinoline derivatives that block acetylcholinesterase and cell calcium signals, and cause neuroprotection against calcium overload and free radicals. <i>European Journal of Medicinal Chemistry</i> , 2006, 41, 1464-1469.	2.6	42
62	New multipotent tetracyclic tacrines with neuroprotective activity. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 8176-8185.	1.4	40
63	Synthesis, acetylcholinesterase inhibition and neuroprotective activity of new tacrine analogues. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 1167-1175.	1.4	55
64	1,6- $\alpha$ -C $\alpha$ H and 1,5- $\alpha$ -O $\alpha$ Si Insertion Reactions of Alkylidenecarbene Derivatives of Monosaccharides*. <i>Journal of Carbohydrate Chemistry</i> , 2005, 24, 369-377.	0.4	11
65	ITH4012 (Ethyl 5-Amino-6,7,8,9-tetrahydro-2-methyl-4-phenylbenzo[1,8]naphthyridine-3-carboxylate), a Novel Acetylcholinesterase Inhibitor with $\alpha$ -Calcium Promotor and Neuroprotective Properties. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 987-994.	1.3	28
66	Synthesis, electrochemical and biological studies on polyfunctionalized 4-ferrocenyl-4H-pyran and 4-ferrocenyl-1,4-dihydropyridine derivatives. <i>Tetrahedron Letters</i> , 2004, 45, 5203-5205.	0.7	11
67	Microwave-Enhanced Reactivity of Non-Activated Dienophiles Towards Pyrazine o-Quinodimethanes.. <i>ChemInform</i> , 2003, 34, no.	0.1	0
68	Microwave-Enhanced Reactivity of Non-Activated Dienophiles Towards Pyrazineo-Quinodimethanes. <i>Synlett</i> , 2002, 2002, 2037-2038.	1.0	10